Remodulin has a mixing option for everyone

Save time with the Remodulin Premix Program

Patients can save time without having to worry about mixing their medicine. Specialty Pharmacy Services and United Therapeutics offer eligible patients taking IV Remodulin the option of having 7- to 14-days* of premixed Remodulin shipped directly to their home. Here's how it works:

The Remodulin Premix Program is for patients who are taking a consistent dose of Remodulin and have been self-mixing for at least 3 months. Based on your doctor's recommendation, this program may be right for you. Ask your doctor about joining.

*
The amount of premixed Remodulin you receive will be dependent on the Specialty Pharmacy.

Premix at home

You can also premix IV Remodulin at home. Reservoirs for IV Remodulin can be premixed up to 14 days in advance when mixing with a sterile high-pH glycine diluent. Remodulin cannot be stored for 14 days when mixed with Sterile Water for Injection or Sodium Chloride Injection. To confirm that you are using a sterile high-pH glycine diluent or to discuss switching to one, contact your healthcare provider or Specialty Pharmacy.

Be sure to use extension tubing with a filter. The CADD-MS® 3 pump should not be used with premixed Remodulin. If you are premixing multiple cartridge syringes, be sure to cap the reservoir tubing or syringe before storing. It’s also important to label each cartridge using the labels provided in your Remodulin Patient Journal or another label of your choice.

Premix label

Make sure to include

  • The date and time you mixed
  • The use-by date and time
  • Vial strength of Remodulin used
  • Amount of diluent used (in milliliters)
  • Amount of Remodulin used (in milliliters)
  • Dosing weight
  • Pump rate
  • Dose

If you have questions, talk with your healthcare provider or Specialty Pharmacy.

Stability was demonstrated as low as 0.004 mg/mL.

Self-mix at home

Remodulin can also be mixed at home at the time of treatment.

Selected Important Safety Information

See the different pump options for IV

Important Safety Information for Remodulin

Indication for Remodulin

Remodulin is a prescription medication used in adults with pulmonary arterial hypertension (PAH; WHO Group 1), to diminish symptoms associated with exercise. PAH is high blood pressure in the arteries of your lungs. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. Remodulin is delivered (infused) continuously using a pump connected to a small tube that is either placed under the skin (subcutaneously [SC]) or inserted into a vein in the upper chest (intravenously [IV]). Because there are risks associated with continuous IV infusion, such as serious blood stream infections, IV infusion should be reserved for people who cannot tolerate SC infusion or for those in whom the risks are considered acceptable.

In people with PAH who need to switch from Flolan® (epoprostenol sodium), Remodulin is approved to slow the worsening of symptoms. The risks and benefits of each drug should be carefully considered before switching.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the Full Prescribing Information for Remodulin.

For additional information, call Customer Service at 1-877-UNITHER (1-877-864-8437).

This information is provided for an informational purpose and is not intended as treatment advice. Patients should consult a healthcare professional for treatment advice.

Important Safety Information and Indication

EXPAND ^

Important Safety Information for Remodulin

  • Continuous intravenous (IV) infusions of Remodulin are delivered using a tube placed in a central vein within the chest. This type of delivery is associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
  • You should not stop or greatly reduce your Remodulin dose without consulting your doctor, as this may cause your PAH symptoms to worsen.
  • Other medical conditions and medicines may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug's effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking.
  • If you have liver or kidney problems, your ability to tolerate Remodulin may be affected.
  • If you are taking gemfibrozil (for high cholesterol), rifampin (for infection), or other drugs that affect liver enzymes, your doctor may need to adjust your Remodulin dosage.
  • Remodulin acts by lowering your blood pressure. In some cases your blood pressure may become too low and cause other side effects. If you also take other drugs that lower your blood pressure, the risk is increased. You should discuss all of your symptoms with your doctor, including those associated with low blood pressure.
  • Because Remodulin can reduce the blood's ability to clot, it may increase your risk of bleeding, especially if you are taking anticoagulants (blood thinners).
  • If you are pregnant, breast-feeding, or planning to become pregnant, talk with your doctor about whether you should take Remodulin.
  • Side Effects: In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness and swelling). These symptoms were often severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain. Other common side effects seen with either SC or IV Remodulin were headache, diarrhea, jaw pain, nausea, vasodilatation (widening of the blood vessels), and edema (swelling).

Indication for Remodulin

Remodulin is a prescription medication used in adults with pulmonary arterial hypertension (PAH; WHO Group 1), to diminish symptoms associated with exercise. PAH is high blood pressure in the arteries of your lungs. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. Remodulin is delivered (infused) continuously using a pump connected to a small tube that is either placed under the skin (subcutaneously [SC]) or inserted into a vein in the upper chest (intravenously [IV]). Because there are risks associated with continuous IV infusion, such as serious blood stream infections, IV infusion should be reserved for people who cannot tolerate SC infusion or for those in whom the risks are considered acceptable.

In people with PAH who need to switch from Flolan® (epoprostenol sodium), Remodulin is approved to slow the worsening of symptoms. The risks and benefits of each drug should be carefully considered before switching.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the Full Prescribing Information for Remodulin.

For additional information, call Customer Service at 1-877-UNITHER (1-877-864-8437).